Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177745
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Elez, Elena | - |
dc.contributor.author | Chianese, Chiara | - |
dc.contributor.author | Sanz-García, Enrique | - |
dc.contributor.author | Martinelli, Erica | - |
dc.contributor.author | Noguerido, Alba | - |
dc.contributor.author | Mancuso, Francesco Mattia | - |
dc.contributor.author | Caratu, Ginevra | - |
dc.contributor.author | Matito, Judit | - |
dc.contributor.author | Grasselli, Julieta | - |
dc.contributor.author | Cardone, Claudia | - |
dc.contributor.author | Esposito, Riziero Esposito | - |
dc.contributor.author | Martini, Giulia | - |
dc.contributor.author | Santos, Cristina | - |
dc.contributor.author | Macarulla, Teresa | - |
dc.contributor.author | Argilés, Guillem | - |
dc.contributor.author | Capdevila, Jaume | - |
dc.contributor.author | Garcia, Ariadna | - |
dc.contributor.author | Mulet Margalef, Núria | - |
dc.contributor.author | Maiello, Evaristo | - |
dc.contributor.author | Normanno, Nicola | - |
dc.contributor.author | Jones, Frederick | - |
dc.contributor.author | Tabernero Caturla, Josep | - |
dc.contributor.author | Ciardello, Fortunato | - |
dc.contributor.author | Salazar Soler, Ramón | - |
dc.contributor.author | Vivancos, Ana | - |
dc.date.accessioned | 2021-05-27T17:09:59Z | - |
dc.date.available | 2021-05-27T17:09:59Z | - |
dc.date.issued | 2019-09-01 | - |
dc.identifier.issn | 1574-7891 | - |
dc.identifier.uri | http://hdl.handle.net/2445/177745 | - |
dc.description.abstract | Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS-mutant allele fraction (MAF) in plasma in mCRC. Forty-seven plasma samples from 37 RAS-mutated patients with nonresectable metastases were tested for RAS in circulating tumor DNA using BEAMing before first- and/or second-line treatment. RAS MAF was correlated with several clinical parameters (number of metastatic sites, hepatic volume, carcinoembryonic antigen, CA19-9 levels, primary site location, and treatment line) and clinical outcome [progression-free survival (PFS) and overall survival (OS)]. An independent cohort of 32 patients from the CAPRI-GOIM trial was assessed for clinical outcome based on plasma baseline MAF. RAS MAF analysis at baseline revealed a significant correlation with longer OS [Hazard ratios (HR) = 3.514; P = 0.00066]. Patients with lower MAF also showed a tendency to longer PFS, although not statistically significant. Multivariate analysis showed RAS MAFs as an independent prognostic factor in both OS (HR = 2.73; P = 0.006) and first-line PFS (HR = 3.74; P = 0.049). Tumor response to treatment in patients with higher MAF was progression disease (P = 0.007). Patients with low MAFs at baseline in the CAPRI-GOIM group also showed better OS [HR = 3.84; 95% confidence intervals (CI) 1.5-9.6; P = 0.004] and better PFS (HR = 2.5; 95% CI: 1.07-5.62; P = 0.033). This minimally invasive test may help in adding an independent factor to better estimate outcomes before initiating treatment. Further prospective studies using MAF as a stratification factor could further validate its utility in clinical practice. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1002/1878-0261.12547 | - |
dc.relation.ispartof | Molecular Oncology, 2019, vol. 13, num. 9, p. 1827-1835 | - |
dc.relation.uri | https://doi.org/10.1002/1878-0261.12547 | - |
dc.rights | cc-by (c) Elez, Elena et al., 2019 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Sang | - |
dc.subject.classification | Genètica | - |
dc.subject.classification | Càncer colorectal | - |
dc.subject.classification | Mortalitat | - |
dc.subject.classification | Mutació (Biologia) | - |
dc.subject.other | Blood | - |
dc.subject.other | Genetics | - |
dc.subject.other | Colorectal cancer | - |
dc.subject.other | Mortality | - |
dc.subject.other | Mutation (Biology) | - |
dc.title | Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 701727 | - |
dc.date.updated | 2021-05-27T17:09:59Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31322322 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701727.pdf | 343.3 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License